| Nov 13 |
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
|
| Nov 9 |
Arcellx Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 8 |
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
|
| Nov 8 |
Arcellx GAAP EPS of -$0.48, revenue of $26.03M
|
| Nov 7 |
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 7 |
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
|
| Nov 7 |
Arcellx price target raised to $106 from $81 at Morgan Stanley
|
| Nov 7 |
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
|
| Nov 6 |
Navigating 7 Analyst Ratings For Arcellx
|
| Nov 5 |
Arcellx issues updates on anito-cel clinical trials
|
